Pleurodynia Treatment Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Diagnosis (Blood test, Culture test, X-ray), By Treatment (Analgesics or Painkillers, Immunoglobulin), By Mode of Administration (Oral, Injections or infusion), By End-User (Hospitals, Pharmacy, Others), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 152.11 Million
CAGR (2026-2031)	5.31%
Fastest Growing Segment	Oral
Largest Market	North America
Market Size (2031)	USD 207.48 Million

Market Overview

The Global Pleurodynia Treatment Market will grow from USD 152.11 Million in 2025 to USD 207.48 Million by 2031 at a 5.31% CAGR. The Global Pleurodynia Treatment Market comprises therapeutic interventions and symptomatic management protocols for Bornholm disease, a viral condition primarily caused by Group B Coxsackieviruses that manifests as spasmodic chest and abdominal pain. The market’s growth is fundamentally supported by the rising incidence of enteroviral infections and significant improvements in molecular diagnostic capabilities, which facilitate the rapid differentiation of viral myalgia from more severe cardiac or pulmonary events. According to the Taiwan Centers for Disease Control, in January 2025, the aggregate number of weekly outpatient and emergency visits for enterovirus infections exceeded 12,350, highlighting the persistent clinical burden that drives the demand for analgesic and anti-inflammatory pharmacotherapies.

A distinct challenge impeding the expansion of this market is the frequent misdiagnosis of the condition due to its non-specific clinical presentation, which often mimics life-threatening emergencies such as myocardial infarction or pulmonary embolism. This diagnostic ambiguity frequently leads healthcare providers to prioritize cardiac workups over viral symptom management, thereby delaying appropriate supportive care and limiting the commercial scope for targeted pleurodynia treatments. Furthermore, the dominance of low-cost generic non-steroidal anti-inflammatory drugs as the primary standard of care creates a low-margin environment that discourages pharmaceutical investment in novel proprietary formulations for this specific indication.

Key Market Drivers

The increasing incidence of Coxsackie B virus and related enteroviral infections is a primary catalyst propelling the Global Pleurodynia Treatment Market, as surging case volumes necessitate robust symptomatic management and diagnostic differentiation. This rising burden of viral myalgia and associated enteroviral conditions compels healthcare systems to prioritize effective analgesic protocols and rapid testing to distinguish Bornholm disease from other acute chest pain etiologies. According to the Taiwan Centers for Disease Control, in September 2025, the number of weekly outpatient and emergency visits for enterovirus infections reached 8,313, signaling a sustained clinical demand for supportive care well beyond the traditional peak seasons. Additionally, the diversity of circulating strains complicates clinical management, further driving the need for precision in treatment approaches. According to the U.S. Centers for Disease Control and Prevention, in June 2025, surveillance data indicated that Enterovirus D68 accounted for 61.6% of reported enterovirus specimens, illustrating the complex viral landscape that providers must navigate when managing pleurodynia-like symptoms.

Concurrently, growing R&D investments in broad-spectrum antiviral therapeutics and vaccines are reshaping the market by fostering the development of novel agents capable of targeting the Picornaviridae family, including Group B Coxsackieviruses. Institutional and government funding is increasingly directed toward bridging the gap between basic virology and clinical application, aiming to introduce targeted therapies that surpass the current standard of non-specific pain relief. For instance, according to BioWorld, in October 2025, the Advanced Research Projects Agency for Health (ARPA-H) awarded approximately $11.8 million to Mount Sinai Medical Center to develop broad-spectrum antiviral therapies. Such financial infusions are critical for advancing pipeline candidates through clinical trials, potentially offering the first disease-modifying treatments for pleurodynia and significantly expanding the commercial potential of the sector.

Download Free Sample Report

Key Market Challenges

The frequent misdiagnosis of Bornholm disease, driven by its non-specific clinical presentation that mimics life-threatening cardiac events, stands as a critical impediment to the growth of the Global Pleurodynia Treatment Market. Because the spasmodic chest pain associated with the condition closely resembles myocardial infarction or pulmonary embolism, healthcare providers are compelled to prioritize extensive cardiac exclusionary workups over immediate viral symptom management. This diagnostic ambiguity delays the administration of appropriate analgesic or anti-inflammatory therapies, effectively narrowing the commercial window for pleurodynia-specific interventions and reducing the realized market volume for targeted treatments.

This disconnect is particularly detrimental given the significant underlying prevalence of the causative viral agents, which often goes unrecognized in the context of specific pleurodynia treatment demand. For instance, according to the UK Health Security Agency, in November 2025, the positivity rate for enterovirus and rhinovirus in monitored respiratory samples reached approximately 20.3%. Despite such high viral circulation, the market fails to capitalize on this patient base because a substantial proportion of these cases are clinically processed as non-specific chest pain or cardiac rule-outs rather than confirmed enteroviral myalgia, thereby suppressing the addressable revenue potential for the market.

Key Market Trends

The transition toward non-opioid analgesic therapies is rapidly reshaping the clinical management of pleurodynia, driven by the critical need to mitigate severe spasmodic chest pain without incurring the risks of opioid dependence. This market shift is characterized by the commercialization of novel sodium channel inhibitors that target peripheral pain signals specifically associated with viral myalgia, providing a sophisticated alternative to the generic non-steroidal anti-inflammatory drugs that currently dominate standard care. According to Vertex Pharmaceuticals, January 2025, the U.S. Food and Drug Administration approved suzetrigine, a first-in-class oral NaV1.8 pain signal inhibitor, which directly addresses the acute pain management needs of approximately 80 million patients annually in the U.S. This regulatory milestone equips healthcare providers with a potent, targeted therapeutic option that aligns with the growing prioritization of opioid-sparing protocols for managing acute viral conditions.

Concurrently, the emergence of mRNA technology applications for enteroviral infections is revolutionizing the development of prophylactic and therapeutic interventions for the Picornaviridae family, including Group B Coxsackieviruses. This trend leverages the adaptability of mRNA platforms to engineer vaccines that can be quickly reformulated to match circulating strains, overcoming the development timelines associated with traditional inactivated candidates. According to a study published in Frontiers in Immunology, February 2025, a nucleoside-modified mRNA vaccine candidate targeting the VP1 protein of Enterovirus A71 demonstrated 100% protection against lethal viral challenge in preclinical models. Such results validate the potential of mRNA technology to deliver precise protection against the specific viral agents responsible for Bornholm disease, signaling a move toward disease-modifying treatments rather than solely symptomatic relief.

Segmental Insights

The Oral segment currently stands as the fastest-growing category within the Global Pleurodynia Treatment Market, attributed largely to the distinct preference for non-invasive administration routes among patients. As the standard medical protocol for pleurodynia involves symptomatic management through analgesics and anti-inflammatory drugs, oral medications ensure higher patient compliance and facilitate effective outpatient care. This ease of self-administration reduces the dependency on clinical visits often required for injectable alternatives. Furthermore, the extensive portfolio of safety-profiled oral formulations authorized by regulatory bodies such as the U.S. Food and Drug Administration supports the continuous expansion of this segment globally.

Regional Insights

North America commands the leading position in the Global Pleurodynia Treatment Market, driven by its highly developed healthcare infrastructure and superior diagnostic capabilities. This dominance is reinforced by the presence of major pharmaceutical entities that actively invest in antiviral research and supportive therapies. Furthermore, the United States Food and Drug Administration establishes a clear regulatory framework that facilitates the efficient approval of essential analgesic and anti-inflammatory medications used for symptom management. These factors, combined with elevated disease awareness among medical professionals, ensure timely diagnosis and effective patient care, securing the region's market superiority.

Recent Developments

• In December 2025, scientists from the University of Maryland, Baltimore County (UMBC) published a study in Nature Communications revealing a highly conserved RNA-protein interaction mechanism critical for the replication of all enteroviruses. The research demonstrated that targeting the interface between the viral RNA "cloverleaf" structure and host proteins could universally disrupt the replication cycle across various enterovirus types, including those linked to myocarditis and pleurodynia. This finding establishes a novel drug target for the Global Pleurodynia Treatment Market, paving the way for the development of "universal" antiviral therapeutics that could provide broad protection against the pathogen family responsible for Bornholm disease.
• In April 2025, a research consortium led by the Norwegian University of Science and Technology (NTNU) announced the identification of a synergistic oral antiviral cocktail capable of halting the replication of diverse enterovirus strains. The combination therapy, which includes pleconaril, AG7404, and mindeudesivir, was shown to effectively inhibit viral activity in human cell cultures and organoids without significant toxicity. This breakthrough is highly relevant to the Global Pleurodynia Treatment Market, as it presents a viable strategy for developing a broad-spectrum oral treatment that could shorten the duration and severity of enterovirus-induced conditions like pleurodynia, for which no approved specific antivirals currently exist.
• In October 2024, researchers at Sichuan University and the Chinese Center for Disease Control and Prevention reported the discovery of a novel peptide, P25, which demonstrated broad-spectrum antiviral efficacy against multiple human enteroviruses. Published in the journal Biomolecules, the study detailed how the peptide, derived from a viral capsid protein, effectively blocked viral entry by competing for cell surface receptors and stabilizing the viral capsid to prevent genome release. This development offers a promising new therapeutic candidate for the Global Pleurodynia Treatment Market, potentially addressing the urgent need for specific antiviral agents to treat the enteroviral infections that cause acute chest pain and muscle spasms.
• In February 2024, Provention Bio (a Sanofi company) released positive data from a Phase I clinical trial evaluating PRV-101, a polyvalent vaccine candidate designed to prevent Coxsackievirus B (CVB) infections. The results, published in Diabetologia, indicated that the vaccine was well-tolerated and successfully elicited high titers of neutralizing antibodies against all five targeted CVB serotypes. As Coxsackievirus B is the primary etiological agent responsible for epidemic pleurodynia (Bornholm disease), this clinical advancement marks a significant step toward a preventative solution in the Global Pleurodynia Treatment Market, which currently relies heavily on supportive symptom management rather than specific prophylaxis.

Key Market Players

• Bristol-Myers Squibb Co
• F. Hoffmann-La Roche Ltd
• Pfizer Inc
• Sanofi SA
• Johnson & Johnson
• Merck & Co Inc.
• GlaxoSmithKline PLC
• Reckitt Benckiser PLC
• Bayer AG
• Novartis AG

By Diagnosis	By Treatment	By Mode of Administration	By End-User	By Region
Blood test Culture test X-ray	Analgesics or Painkillers Immunoglobulin	Oral Injections or infusion	Hospitals Pharmacy Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Pleurodynia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Pleurodynia Treatment Market, By Diagnosis:

• Blood test
• Culture test
• X-ray

• Pleurodynia Treatment Market, By Treatment:

• Analgesics or Painkillers
• Immunoglobulin

• Pleurodynia Treatment Market, By Mode of Administration:

• Oral
• Injections or infusion

• Pleurodynia Treatment Market, By End-User:

• Hospitals
• Pharmacy
• Others

• Pleurodynia Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE